Fintel reports that on June 6, 2025, Goldman Sachs initiated coverage of Teva Pharmaceutical Industries Limited - Depositary ...

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection ...

A new study from Teva Pharmaceutical Industries Limited (NYSE:TEVA) has uncovered alarming gaps in the diagnosis and ...

Sound Shore Management, an investment management firm, has released its investor letter for the first quarter of 2025. A copy ...

My name is Dennis Ding, biotech analyst here at Jefferies. I have the great pleasure of having Teva here with us. Welcome. Sure. Yes. So we have been on an amazing journey, and it's been a really ...

Teva Pharmaceutical Industries Ltd. announced early results for its tender offers regarding multiple series of senior notes to proactively manage its debt capital structure and extend maturity ...

In 2020, we committed to launching eight Access to Medicines programs by 2025, aimed at providing treatments to underserved ...

Teva Pharmaceutical Industries (TEVA) announced the pricing and early acceptance results of its previously announced tender offers to buy for cash the outstanding notes.

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, ...

Investing.com -- Goldman Sachs initiated coverage on U.S.-listed generic pharmaceutical companies with Buy ratings on Teva ...

Upon the terms and subject to the conditions set forth in the Offer to Purchase, the early acceptance results and the Total Consideration for each applicable series of the Notes are set forth in the ...

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibodyDesignation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celia ...